HSBC set a €82.00 ($95.35) price objective on Bayer (FRA:BAYN) in a report released on Wednesday. The brokerage currently has a neutral rating on the healthcare company’s stock.

Several other analysts have also issued reports on the stock. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of Bayer and gave the stock a buy rating in a research report on Thursday, June 21st. Sanford C. Bernstein set a €115.00 ($133.72) price target on shares of Bayer and gave the stock a buy rating in a research report on Wednesday, September 5th. Cfra set a €100.00 ($116.28) price target on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, August 14th. Independent Research set a €85.00 ($98.84) price target on shares of Bayer and gave the stock a neutral rating in a research report on Wednesday, September 5th. Finally, Commerzbank set a €111.00 ($129.07) price target on shares of Bayer and gave the stock a buy rating in a research report on Monday, August 20th. Eight investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Bayer presently has an average rating of Buy and an average target price of €100.34 ($116.68).

Shares of BAYN stock opened at €75.97 ($88.34) on Wednesday. Bayer has a 12 month low of €91.58 ($106.49) and a 12 month high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Market Capitalization and Individual Investors

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.